All In Biotech

Drug Trial Radar · NCT06880770

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Apr 24, 2025

Primary completion

Mar 2029

Study completion Jun 2029

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.

Conditions

  • Severe Hypertriglyceridemia

Interventions

  • PlozasiranDrug

    ARO-APOC3 injection

  • PlaceboDrug

    sterile normal saline (0.9% NaCl)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Positively Adjudicated AP Event (Event Occurring More Than 10 Days After First Dose of Study Drug)Time frame: Randomization up to end of Double Blind Treatment Period compared to placebo (Approximate Maximum 50 Months)]

Locations

140 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California · Recruiting

  • Clinical Research Site 4

    Santa Clarita, California · Recruiting

  • Research Site

    New Haven, Connecticut · Recruiting

  • Clinical Research Site 6

    Springfield, Illinois · Recruiting

  • Research Site

    Indianapolis, Indiana · Recruiting

  • Research Site

    Kansas City, Kansas · Recruiting

  • Research Site

    Ann Arbor, Michigan · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Clinical Research Site 5

    North Platte, Nebraska · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Clinical Research Site 3

    Greensboro, North Carolina · Recruiting

  • Research Site

    Wilmington, North Carolina · Recruiting

  • Clinical Research Site 7

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Clinical Research Site 1

    Mesquite, Texas · Recruiting

  • Clinical Research Site 2

    San Antonio, Texas · Recruiting

  • Research Site

    Seattle, Washington · Recruiting

  • Research Site

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Research Site

    Ramos Mejía, Buenos Aires, Argentina · Recruiting

  • Research Site

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Research Site

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Research Site

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Research Site

    Graz, Austria · Recruiting

  • Research Site

    Linz, Austria · Recruiting

  • Research Site

    Vienna, Austria · Recruiting

  • Research Site

    Brussels, Belgium · Recruiting

  • Research Site

    Ghent, Belgium · Recruiting

  • Research Site

    São Paulo, Brazil · Recruiting

  • Research Site

    Fortaleza, Ceará, Brazil · Recruiting

  • Research Site

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Research Site

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Research Site

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Research Site

    Curitiba, Paraná, Brazil · Recruiting

  • Research Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Research Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Research Site

    Pôrto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Research Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Research Site

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • Research Site

    Burgas, Bulgaria · Recruiting

  • Research Site

    Dimitrovgrad, Bulgaria · Recruiting

Showing 40 of 140 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.